88
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival

, , , , , , , & show all
Pages 1476-1479 | Received 01 Mar 2023, Accepted 10 May 2023, Published online: 31 May 2023
 

Acknowledgements

This registry was granted by Celgene and Novartis. We thank M. Hellmich (Institute of Medical Statistics and Computational Biology, Cologne, Germany) for statistical support and all participating hematologists for the contribution of data.

Disclosure statement

The authors report no conflicts of interest.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.